<DOC>
	<DOC>NCT02631863</DOC>
	<brief_summary>This trial will study the effectiveness of photodynamic therapy with aminolaevulinic acid for the treatment of patients with HPV+ low grade cervical intraepithelial neoplasia (LSIL;CIN1).</brief_summary>
	<brief_title>Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma in Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Premenopausal women, 2550 years of age Diagnosed with LSIL/CIN1 by local pathology (biopsy) and highrisk HPV positive by HC2 assay within the last 3 months Satisfactory colposcopy examination (visibility of entire transformation zone and entire lesion margin ) Meet the following conditions: pregnancy test negative; no pregnancy plan during the trial; no sexuality or reliable contraceptive measures taken since last menstruation to the onset of the study, agreeing to adopt reliable contraceptive measures during the study Written informed consent signed ASCH (atypical squamous cells, cannot exclude HSIL) or HSIL (highgrade squamous intraepithelial lesions) or AGC (atypical glandular cells) or AIS (adenocarcinoma in situ) on cytology, or malignant cells on cytology or histology, or other suspicion of either microinvasive or invasive disease Invasive carcinoma possibility or lesions extending to the vaginal vault or suspicion of endocervical disease on colposcopy Severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per clinical examination Undiagnosed vaginal bleeding With allergic disease at present; known or suspected porphyria; known allergy to ALA or analogues With serious cardiovascular, neurologic, psychiatric, endocrine, hematological disease; immunocompromised conditions; patients with malignant tumors Hepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase or total bilirubin &gt; 1.5 upper limit of normal [ULN], or serum creatinine or blood urea nitrogen &gt; 1.5 ULN) Pregnancy or nursing Previous physical therapy of LSIL/CIN1 after pathologic diagnosis Participation in any clinical studies within the last 30 days Subjects that the investigators judged to be not suitable to participate the study besides above</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>